EDEN PRAIRIE, Minn., July 1 /PRNewswire/ -- Celleration, Inc., developer of the patented MIST Therapy(R) System, an innovative device that uses ultrasound to heal wounds, has named Mark T. Wagner as president and chief executive officer and member of Celleration's board of directors. Mr. Wagner brings a successful track record of developing and commercializing medical devices spanning 30 years to the Celleration team.
"We are delighted by the addition of Mark to the Celleration team," said Ed Spencer, Jr., Chairman of Affinity Capital Management and Chairman of Celleration's board of directors. "Mark brings a wealth of experience and a solid history of building companies and delivering results. We are absolutely confident in Mark's ability to take Celleration to its next stage of commercialization and build value for its shareholders."
Mr. Wagner has decades of leadership experience in the medical device field. Most recently, he co-founded and is Board Chairman of Orasi Medical, a spinout from the
Kevin Nickels, the previous CEO, will continue to serve as the Chief Technology and Business Development Officer. Mr. Spencer commented, "During his seven years as CEO, Kevin made a huge contribution to the development of the business and I am delighted that we will continue to have the benefit of his vision in his new role as Chief Technology and Business Development Officer."
About Celleration, Inc.:
Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology delivers non-contact, low-frequency, low-intensity ultrasound to the patient's injured soft tissue in a painless fashion. The chronic diabetic foot ulcer market had been the Company's initial focus. MIST Therapy(R) has since expanded to various hard to heal, chronic wounds benefiting from higher incidence of complete healing in less time than standard of care. The end results, improving patient outcomes at a lower cost to the health care industry. In addition to the Company's prospective, randomized, double-blind, sham-controlled multi-center study in diabetic foot ulcers, which resulted in a statistically significant improvement in the rate of wound closure and time to wound closure, numerous independent clinical researchers without funding from the Company has further validated this value proposition.
Contacts: Chris Geyen, Chief Financial Officer 952-224-8700 Richard Lewis Communications, Inc. 212-827-0020 Andrew Mielach, Media firstname.lastname@example.org Cecelia Heer, Investors email@example.com
|SOURCE Celleration, Inc.|
Copyright©2009 PR Newswire.
All rights reserved